Literature DB >> 11369414

Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin.

E Dupuy1, C Soria, P Molho, J M Zini, S Rosenstingl, C Laurian, P Bruneval, G Tobelem.   

Abstract

Fibrinogen plays a complex role in hemostasis, thrombosis, and vascular disease. Hyperfibrinogenemia is an independent vascular risk factor and dysfibrinogenemia can provoke thrombosis. Afibrinogenemia is usually responsible for hemorrhagic diathesis, and unexpected ischemic lesions are intriguing. We report the case of an afibrinogenemic patient, who at the age of 30 developed ischemic lesions of the feet related to severe stenosis of the iliac and hypogastric arteries. The biopsy of the iliac artery lesion showed an intense myointimal hyperplasia. We performed standard hemostatic analysis and analyzed the activation markers of platelets and coagulation factors and the kinetics of thrombin generation in the patient and in normal control plasmas treated or not with reptilase. Occlusive arterial lesions were attributed to a disruptive hematoma penetrating the vascular lumen. Thrombin concentration after calcium addition increase markedly in the afibrinogenemic patient and in defibrinated normal plasma, as compared to untreated normal plasma. Thrombin-antithrombin complexes (T-AT) were markedly enhanced while F1+2 prothrombin fragments stayed in the normal range. These results suggested activation of coagulation and in vivo circulating thrombin. Thrombin activates the platelets that secrete growth factors for smooth muscle cells and generate the intimal hyperplasia. Recurrent hemorrhage within the vessel wall might induce injury and local thrombin generation. Thrombin not trapped by the clot is available for platelet activation and smooth muscle cell migration and proliferation. The absence of a protective fibrin cap on the intima might account for intima vulnerability and embolization. Afibrinogenemia appears in this paradoxical situation as a vascular risk factor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369414     DOI: 10.1016/s0049-3848(01)00247-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  15 in total

1.  Budd-Chiari syndrome in an afibrinogenemic patient: a paradoxical complication.

Authors:  Nevin Oruc; Yaman Tokat; Refik Killi; Murat Tombuloglu; Tankut Ilter
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

Review 2.  Thrombosis in Inherited Fibrinogen Disorders.

Authors:  Wolfgang Korte; Man-Chiu Poon; Alfonso Iorio; Michael Makris
Journal:  Transfus Med Hemother       Date:  2017-03-14       Impact factor: 3.747

3.  Activation of factor XI by products of prothrombin activation.

Authors:  Anton Matafonov; Suryakala Sarilla; Mao-fu Sun; John P Sheehan; Vladimir Serebrov; Ingrid M Verhamme; David Gailani
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

Review 4.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

5.  Primed to Understand Fibrinogen in Cardiovascular Disease.

Authors:  Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01       Impact factor: 8.311

6.  Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease.

Authors:  Pichika Chantrathammachart; Nigel Mackman; Erica Sparkenbaugh; Jian-Guo Wang; Leslie V Parise; Daniel Kirchhofer; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2012-06-01       Impact factor: 22.113

7.  Acute myocardial infarction in a patient with hypofibrinogenemia: a case report.

Authors:  Fathia Mghaieth; Habiba Mizouni; Sihem Mbarki; Jihen Ayari; Ramy Trabelsi; Nidhal Ben Moussa; Mohamed Sami Mourali; Emna Mnif; Rachid Mechmeche
Journal:  J Med Case Rep       Date:  2011-12-19

8.  Comparative study of the effect of rivaroxaban and fondaparinux on monocyte's coagulant activity and cytokine release.

Authors:  Marc Laurent; Ulrich Joimel; Rémi Varin; Lionel Cazin; Caroline Gest; Veronique Le-Cam-Duchez; Jian Jin; Jielin Liu; Jean-Pierre Vannier; He Lu; Jeannette Soria; Hong Li; Claudine Soria
Journal:  Exp Hematol Oncol       Date:  2014-12-17

Review 9.  Clinical Consequences and Molecular Bases of Low Fibrinogen Levels.

Authors:  Marguerite Neerman-Arbez; Alessandro Casini
Journal:  Int J Mol Sci       Date:  2018-01-08       Impact factor: 5.923

Review 10.  Treatment of congenital fibrinogen deficiency: overview and recent findings.

Authors:  Konstantinos Tziomalos; Sofia Vakalopoulou; Vassilios Perifanis; Vassilia Garipidou
Journal:  Vasc Health Risk Manag       Date:  2009-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.